This post is from a suggested group
Liquid Biopsy: Revolutionizing Cancer Detection and Management
Liquid biopsy has emerged as one of the most promising innovations in the field of oncology, transforming the way clinicians detect, monitor, and manage cancer. Unlike traditional tissue biopsies, which require invasive procedures to obtain tumor samples, liquid biopsy relies on analyzing biomarkers present in body fluids such as blood, urine, or saliva. This minimally invasive approach offers significant advantages for patients, enabling safer and more frequent testing.
At the core of liquid biopsy is the detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other molecular fragments released by cancerous cells into the bloodstream. These biomarkers provide critical insights into the genetic and molecular characteristics of a tumor. By identifying specific mutations, clinicians can tailor personalized treatment strategies, increasing the likelihood of treatment success and minimizing unnecessary side effects.
One of the most significant applications of liquid biopsy is…